Tryptamine Therapeutics Limited

ASX:TYP Stock Report

Market Cap: AU$57.4m

Tryptamine Therapeutics Past Earnings Performance

Past criteria checks 0/6

Tryptamine Therapeutics has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 176.4% per year.

Key information

0.3%

Earnings growth rate

56.7%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate176.4%
Return on equity-131.2%
Net Margin-555.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Tryptamine Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:TYP Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-740
29 Feb 240-531
30 Nov 230-532
31 Aug 230-620
31 May 230-724
28 Feb 230-624
30 Nov 220-734
31 Aug 220-853
31 May 220-962
28 Feb 220-1182
30 Nov 210-1292
31 Aug 210-971
31 May 210-650

Quality Earnings: TYP is currently unprofitable.

Growing Profit Margin: TYP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TYP is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.

Accelerating Growth: Unable to compare TYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TYP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).


Return on Equity

High ROE: TYP has a negative Return on Equity (-131.15%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies